Results 31 to 40 of about 2,404 (154)

Evaluation of nirsevimab against rsv infection in infants

, 2023
19 p.ill.,LIST OF TABLES 1 -- BACKGROUND 3 -- 1 BACKGROUND 4 -- 2 METHODS 4 -- 3 CLINICAL EVIDENCE 7 -- 3.1 NIRSEVIMAB IN PRETERM INFANTS 7 -- 3.2 NIRSEVIMAB IN LATE-PRETERM AND TERM INFANTS 9 -- 3.3 MEDLEY TRIAL 14 -- 3.4 HARMONIE TRIAL (PRELIMINARY ...
Desimpel, Fabian
core   +1 more source

Comparative Analysis of Reported Adverse Events with Nirsevimab and Palivizumab in the FAERS Database. [PDF]

Kans J Med
Introduction. Respiratory syncytial virus (RSV) remains a leading cause of hospitalization among infants. Palivizumab has long been used for RSV prophylaxis in high-risk infants, whereas nirsevimab is a newer long-acting monoclonal antibody approved for ...
Touffaha I, Ablah E, Okut H, Homan G.
europepmc   +2 more sources

Assessing the Effects of Nirsevimab on Respiratory Syncytial Virus Bronchiolitis Outcomes: Insights From A Two‐Season Analysis [PDF]

Pediatr Pulmonol
ABSTRACT Objectives Nirsevimab was approved in Europe in 2022 for respiratory syncytial virus (RSV) prevention. In October 2023, Catalonia (Spain) launched a universal immunization program for infants under 6 months during their first RSV season. This study aims to assess the characteristics of patients admitted with bronchiolitis following nirsevimab ...
Agüera M, Soler‐Garcia A, Castellà S, Moussalam‐Merino S, Alejandre C, Penela‐Sánchez D, Esteva C, Fortuny C, Fernández de Sevilla M, García‐García J, Jordan I, Muñoz‐Almagro C, Launes C.   +12 more
europepmc   +2 more sources

Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children [PDF]

Clinical and Experimental Pediatrics
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (LRTIs) in infants and young children. In April 2024, the Korea Ministry of Food and Drug Safety approved nirsevimab (Beyfortus), a long-acting monoclonal ...
Soo-Han Choi, Dong Hyun Kim, Jong Gyun Ahn, Ki Wook Yun, Byung-Wook Eun, Jin Lee, Jina Lee, Taek-Jin Lee, Hyunju Lee, Dae Sun Jo, Eun Young Cho, Hye-Kyung Cho, Young June Choe, Ui Yoon Choi, Yun-Kyung Kim, The Committee on Infectious Diseases of the Korean Pediatric Society   +15 more
doaj   +1 more source

Sociodemographic and Clinical Factors Associated With Nirsevimab Receipt Among Children Aged Younger Than 20 Months in the New Vaccine Surveillance Network in 2023 to 2025. [PDF]

Hosp Pediatr
OBJECTIVES We aim to evaluate the association of sociodemographic and clinical factors with nirsevimab receipt among children with medically attended acute respiratory illness (ARI) across multiple seasons and ...
Teoh Z, Tannis A, Sullivan E, Boom JA, Halasa N, Michaels MG, Payne DC, Sahni LC, Schuster J, Selvarangan R, Staat MA, Stewart LS, Szilagyi PG, Weinberg GA, Williams JV, Dawood FS, Klein EJ, Moline H, Englund JA, Zerr DM.   +19 more
europepmc   +2 more sources

First real-world data on universal respiratory syncytial virus prophylaxis with Nirsevimab in infants [PDF]

Respiratory syncytial virus (RSV) predominantly affects young children, with a peak incidence in temperate regions of the northern hemisphere from October to May.
Scarpaleggia M., Rizzo C, Baldo V., Chironna M., Pariani E, Baldo V, Orsi A, Scarpaleggia M, Icardi G, Orsi A., Panatto D, Pariani E., Giuffrida S., Panatto D., Icardi G., Barbone F, Rizzo C., Giuffrida S, Barbone F., Montomoli E., Chironna M, Montomoli E   +20 more
core   +3 more sources

The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis

Frontiers in Pediatrics, 2023
BackgroundRespiratory syncytial virus (RSV) is a leading cause of morbidity and mortality among infants with a global incidence of 9.5% and a mortality rate of 2.2%. The management of RSV infection is mainly supportive and, aside from emerging monoclonal
Maria Wilma R. Turalde-Mapili, Jerahmeel Aleson L. Mapili, Christian Wilson R. Turalde, Christian Wilson R. Turalde, Marimel R. Pagcatipunan   +4 more
doaj   +1 more source

Cost-effectiveness and public health impact of RSV immunization for all infants in Japan: a mixed strategy with nirsevimab and RSVpreF

Expert Review of Vaccines
Background Respiratory syncytial virus (RSV) remains a leading cause of medically attended lower respiratory tract disease (MA-LRTD) among infants in Japan.
Naruhiko Ishiwada, Xinyu Wang, Takeshi Arashiro, Camille Reygrobellet, Benjamin Yarnoff, Robert Musci, Mehdi Ghemmouri   +6 more
doaj   +1 more source

Acceptance and safety of the RSV-preventive treatment of newborns with nirsevimab in the maternity department: a prospective longitudinal cohort study in FranceResearch in context

EClinicalMedicine
Summary: Background: To evaluate the acceptance and safety of the treatment of newborns with nirsevimab (a long-acting monoclonal antibody designed to prevent respiratory syncytial virus infections) during the first season of implementation.
Charlotte Ocana de Sentuary, Clara Testard, Marion Lagrée, Maxime Leroy, Lisa Gasnier, Alicia Enes-Dias, Constance Leruste, Diariatou Diallo, Michael Génin, Thameur Rakza, François Dubos   +10 more
doaj   +1 more source

Coverage, Timing, Safety, and Determinants of Neonatal Intensive Care Unit Admission in Newborns Receiving Nirsevimab Prophylaxis for Respiratory Syncytial Virus. [PDF]

Pathogens
Background: Nirsevimab, a long-acting monoclonal antibody targeting respiratory syncytial virus (RSV), has recently been introduced as universal prophylaxis in newborns and infants. Although clinical trials have shown high efficacy and a favorable safety
Costantino M, Giudice V, Della Corte AM, Pecoraro S, Frascogna AR, Marchesano G, Moschella S, Alfano C, Santaniello F, Brengola C, Napoletano G, Caputo V, Luciano A, Santullo A, Pierri L, Aiello F, De Caro MC, Catena L, Sarnataro C, De Caro F, Corbo MG.   +20 more
europepmc   +2 more sources